A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Source: View publication →
The MR CLEAN trial demonstrated that among patients with acute ischemic stroke caused by a proximal anterior circulation occlusion, endovascular treatment (mostly mechanical thrombectomy) plus usual care resulted in better functional outcomes at 90 days compared to usual care alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
MR CLEAN provided the first definitive, high-quality evidence that endovascular thrombectomy, when added to standard medical care, significantly improves functional recovery in patients with large-vessel occlusion ischemic stroke. This trial served as the catalyst for a paradigm shift in global stroke management protocols and established endovascular therapy as the standard of care for eligible patients.
Historical Context
Prior to MR CLEAN, several major trials (such as IMS III, MR RESCUE, and SYNTHESIS Expansion) had failed to demonstrate a clear benefit of endovascular intervention over intravenous thrombolysis, leading to widespread skepticism in the neurological community. The positive results of MR CLEAN, driven largely by modern stent-retriever technology, effectively 'redeemed' mechanical thrombectomy and prompted a rapid evolution in clinical stroke practice worldwide.
Guided Discussion
High-yield insights from every perspective
Why are proximal occlusions of the anterior circulation (like the M1 segment of the MCA) less likely to achieve recanalization with intravenous alteplase alone compared to more distal occlusions?
Key Response
Large-vessel occlusions (LVOs) involve a higher thrombus burden and a smaller surface-area-to-volume ratio for the thrombolytic agent to act upon. Studies suggest the recanalization rate for proximal ICA or M1 occlusions with IV tPA is often below 10-25%, necessitating mechanical intervention to physically remove the clot and restore perfusion.
In a patient who is a candidate for both IV thrombolysis and endovascular treatment according to MR CLEAN criteria, should the initiation of the endovascular procedure be delayed to assess the clinical response to the IV bolus?
Key Response
No. Management should follow a 'bridge therapy' approach. MR CLEAN and subsequent meta-analyses demonstrate that endovascular treatment should be initiated as soon as possible. Delaying thrombectomy to 'wait and see' if IV tPA works results in lost neurons (time-is-brain) and worse functional outcomes. The trial showed benefit regardless of whether IV tPA was administered.
MR CLEAN utilized a pragmatic approach to imaging selection, primarily requiring a proximal occlusion on CTA rather than a specific core/penumbra volume on CTP. How does this impact the 'number needed to treat' (NNT) compared to later trials like EXTEND-IA which used advanced perfusion imaging?
Key Response
MR CLEAN had a broader inclusion, resulting in an NNT for functional independence of approximately 7. Trials with stricter perfusion imaging selection (like EXTEND-IA) showed higher effect sizes and lower NNTs (around 3) by excluding patients with large completed infarcts or poor collateral flow. However, MR CLEAN proved that even without advanced imaging, the benefit of thrombectomy is robust in a real-world setting.
The MR CLEAN trial demonstrated a significant shift in the modified Rankin Scale (mRS) distribution but did not show a significant reduction in mortality. How should this distinction shape the goals-of-care discussion with a surrogate for a patient with a high-NIHSS stroke?
Key Response
The intervention improves the quality of survival (functional independence) rather than the quantity (mortality). Clinicians must explain that while thrombectomy significantly increases the chance of the patient returning to a life without disability (mRS 0-2), it does not necessarily prevent the most severe strokes from being fatal. The 'shift' analysis is the key teaching point here.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
MR CLEAN utilized an ordinal analysis (proportional-odds model) for its primary endpoint. What are the specific statistical assumptions required for this 'shift analysis' to be valid, and how does it compare in power to a dichotomous (Fisher’s exact) approach?
Key Response
The shift analysis assumes 'proportional odds,' meaning the effect of treatment is consistent across all transition points of the mRS (e.g., the benefit of moving from mRS 4 to 3 is statistically treated with the same weight as 2 to 1). This approach significantly increases statistical power compared to a dichotomous 'all-or-nothing' endpoint (mRS 0-2 vs 3-6) because it utilizes the data from every patient in the distribution.
MR CLEAN was published shortly after three major trials (IMS III, SYNTHESIS Expansion, and MR RESCUE) failed to show a benefit for endovascular therapy. What specific trial design changes in MR CLEAN addressed the fatal flaws of those previous studies?
Key Response
The three critical improvements were: 1) Mandatory vascular imaging (CTA/MRA) to confirm a target occlusion; 2) The predominant use of second-generation 'stent-retrievers' rather than older, less effective Merci/Penumbra devices; and 3) Faster time-to-treatment. As an editor, the 'threat to validity' in previous trials was the inclusion of patients without confirmed LVOs, which MR CLEAN corrected by ensuring only those who could theoretically benefit were enrolled.
How did the MR CLEAN results change the AHA/ASA Class of Recommendation for mechanical thrombectomy, and what gaps did it leave regarding the ASPECTS score threshold?
Key Response
MR CLEAN, as the first of the 'five pillars' of modern thrombectomy trials, led to the upgrade of mechanical thrombectomy to a Class I, Level A recommendation for patients within 6 hours of onset with an M1 or ICA occlusion. However, because it included few patients with low ASPECTS (<6), early guidelines remained conservative about treating patients with large established infarcts, a gap only recently addressed by trials like SELECT2 and ANGEL-ASPECTS.
Clinical Landscape
Noteworthy Related Trials
ESCAPE Trial
Tested
Endovascular thrombectomy plus standard care
Population
Patients with acute ischemic stroke and intracranial vessel occlusion
Comparator
Standard care alone
Endpoint
Functional independence at 90 days (modified Rankin Scale 0-2)
EXTEND-IA Trial
Tested
Solitaire FR stent retriever thrombectomy
Population
Acute ischemic stroke patients with large vessel occlusion
Comparator
Intravenous alteplase only
Endpoint
Reperfusion at 24 hours and early neurologic improvement
SWIFT PRIME Trial
Tested
Solitaire stent retriever thrombectomy within 6 hours
Population
Patients with acute ischemic stroke and occlusion of intracranial internal carotid or middle cerebral artery
Comparator
Intravenous t-PA alone
Endpoint
Functional independence at 90 days (modified Rankin Scale 0-2)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis